Video
Mark Cuban Cost Plus Drug Company confers savings on urologic drugs
Author(s):
“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.
Video Player is loading.
In this video, Ruchika Talwar, MD, discusses the background and notable findings from the Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.
Related Videos
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Ruchika Talwar, MD, discusses ongoing drug shortages in urology
Dr Louise Kostos discusses PSA kinetics in mHSPC
Related Content
